-
-
-
-
-
-
-
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
-
-
-
-
-
-
-
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Misses Q2 EPS by 30c
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c
-
-
-
-
-
-
-
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c
-
1,211,669 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

